Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2006

View Archived Issues

Gene therapy for spinal muscular atrophy / News in context

MAP Pharmaceuticals closes Series C financing

Callisto licenses degrasyns from M.D. Anderson

Durect expands SABER-Bupivacaine development program

Abbott highlights fourth quarter achievements

Bristol-Myers Squibb recaps recent events

New treatments for cancer covered in recent patents

Immunosuppressive activity of a newly isolated natural product

New compounds display dual BLT/TRPV1 antagonism

FDA Advisory Committee sets date for Tysabri review in MS

Amendment to BLP-25 Liposome Vaccine licensing agreement

Phase I study begins for Nanoplatin

First animal efficacy data for PhGalpha1

Photofrin studied for superficial cancerous and precancerous lesions of the mouth

Japanese manufacturing approval for Loxonin poultice

Pharmexa begins phase I study for HIV vaccine candidates

European orphan drug designation for 1D09C3 in CLL

CIP-Tramadol ER NDA planned for Q2 2006

Japanese filing for nateglinide in combination with biguanide agents

Creatine safe in Huntington's disease; further study under way

Bortezomib sensitizes multiple myeloma to radiation in vivo

Recent patents cover therapeutic agents for neurological disorders

Novel antiinfective agents described in recent patents

Remicade recommended for approval for ulcerative colitis in Europe

Avanir submits expanded Neurodex NDA

European CHMP hands down positive opinion for Lyrica in GAD

European approval for Ionsys in postoperative pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...